Risperidone and Felbamate drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Risperidone (risperidone) and Felbamate (felbamate). Common drug interactions include drug administration error among females and cerebral haematoma among males.

The phase IV clinical study analyzes what interactions people have when they take Risperidone and Felbamate. It is created by eHealthMe based on reports of 16 people who take the same drugs from the FDA, and is updated regularly.

What is Risperidone?

Risperidone has active ingredients of risperidone. It is often used in bipolar disorder. eHealthMe is studying from 72,175 Risperidone users. Check the latest studies of Risperidone.

What is Felbamate?

Felbamate has active ingredients of felbamate. eHealthMe is studying from 1,145 Felbamate users. Check the latest studies of Felbamate.



On Jul, 19, 2026

16 people who take Risperidone and Felbamate together, and have interactions are studied.

Risperidone and Felbamate drug interactions.

What are the common drug interactions of Risperidone and Felbamate, by gender? *:

female:

  1. Drug administration error
  2. Emotional disorder
  3. Cough
  4. Drooling (drop saliva uncontrollably from the mouth)
  5. Nasopharyngitis (inflammation of the nasopharynx)
  6. Abnormal behaviour

male:

  1. Cerebral haematoma (collection of blood in brain)
  2. Ear infection
  3. Fall
  4. Fatigue (feeling of tiredness)
  5. Head injury
  6. Hepatic adenoma (benign liver tumour)
  7. Nasopharyngitis (inflammation of the nasopharynx)
  8. Nystagmus (a condition of involuntary eye movement)
  9. Sedation

What are the common drug interactions of Risperidone and Felbamate, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

  1. Cough
  2. Drooling (drop saliva uncontrollably from the mouth)
  3. Hepatic adenoma (benign liver tumour)
  4. Nasopharyngitis (inflammation of the nasopharynx)

20-29:

  1. Ear infection
  2. Nasopharyngitis (inflammation of the nasopharynx)

30-39:

n/a

40-49:

n/a

50-59:

n/a

60+:

n/a

What are the existing conditions these people have? *

  1. Tuberous Sclerosis (a rare genetic disease that causes benign tumours to grow in the brain and other organs): 4 people, 25.00%
  2. Lennox-Gastaut Syndrome (epilepsy characterized by frequent seizures and different seizure types): 4 people, 25.00%
  3. Seizures (abnormal excessive or synchronous neuronal activity in the brain): 3 people, 18.75%
  4. Epilepsy (common and diverse set of chronic neurological disorders characterized by seizures): 3 people, 18.75%
  5. Idiopathic Generalised Epilepsy (epileptic disorders that are believed to have a strong underlying genetic basis): 2 people, 12.50%
  6. Sleep Disorder: 1 person, 6.25%
  7. Emotional Disorder: 1 person, 6.25%
  8. Blood Glucose Fluctuation: 1 person, 6.25%
  9. Agitation (state of anxiety or nervous excitement): 1 person, 6.25%
  10. Abnormal Behavior: 1 person, 6.25%

* Approximation only. Some reports may have incomplete information.

Do you take Risperidone and Felbamate?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Risperidone and Felbamate:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Risperidone:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Felbamate:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Risperidone and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Felbamate and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Related publications that referenced our studies


How the study uses the data?

The study uses data from the FDA. It is based on risperidone and felbamate (the active ingredients of Risperidone and Felbamate, respectively), and Risperidone and Felbamate (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: